Baskent University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Ankara Turkey (1994)

Organization Overview

First Clinical Trial
2000
NCT02658799
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Baskent University | Baskent University Ankara Hospital | Baskent University Department of Anesthesiology | Baskent University Departments of Obstetrics and Gynecology | Başkent University Endocrinolgy Dep | Başkent University, Faculty of Health Science, Department of Nursing | Baskent University Faculty of Medicine | Baskent University, Faculty of Medicine | Baskent University Faculty of Medicine, Department of Pulmonary Disease | Baskent University, Physiotherapy and Rehabilitation Department | Baskent University School of Dentistry | Baskent University School of Medicine | Baskent Univesity Ankara Hospital | H. Evren Eker | Omer Karaca | Paediatric Nephrology Division, Department of Paediatrics, Faculty of Medicine, Baskent University, Ankara, Turkey | Pinar Ergenoglu | Zuhal Ekici Unsal

Active Ingredients

Drugs in Phase 4 Trials (26)

acetaminophen (tylenol) (5 trials)

aprepitant (Emend) (1 trial)

atorvastatin (lipitor) (1 trial)

calcium phosphate (1 trial)

codeine (Phenergan) (1 trial)

dexmedetomidine (precedex) (3 trials)

etomidate (amidate) (1 trial)

fentanyl (Innovar) (2 trials)

glucose (2 trials)

granisetron (kytril) (1 trial)

ketamine (ketalar) (2 trials)

lidocaine (xylocaine) (1 trial)

midazolam (versed) (4 trials)

morphine (1 trial)

naproxen (naprosyn) (1 trial)

oxybutynin (ditropan) (1 trial)

oxygen (1 trial)

pregabalin (lyrica) (1 trial)

propofol (diprivan) (2 trials)

remifentanil (ultiva) (1 trial)

sevoflurane (ultane) (1 trial)

simvastatin (zocor) (1 trial)

sitagliptin (januvia) (4 trials)

sodium chloride (2 trials)

solifenacin (vesicare) (1 trial)

sugammadex (bridion) (1 trial)

Drugs in Phase 3 Trials (18)

atropine (1 trial)

betamethasone (celestone) (1 trial)

cefixime (suprax) (1 trial)

clavulanate (Augmentin) (1 trial)

dexibuprofen (1 trial)

diclofenac (voltaren) (2 trials)

diphenhydramine (benadryl) (1 trial)

ephedrine (1 trial)

levobupivacaine (chirocaine) (2 trials)

losartan (cozaar) (1 trial)

meperidine (demerol) (1 trial)

metoclopramide (reglan) (1 trial)

nifedipine (procardia) (1 trial)

nitrofurantoin (furadantin) (1 trial)

platelet-rich plasma (2 trials)

procaine benzylpenicillin (novocaine) (1 trial)

sufentanil (1 trial)

trimethoprim (1 trial)

Drugs in Phase 2 Trials (1)

metamizole (Novalgin) (1 trial)

Drugs in Other Trials (10)

bupivacaine (Exparel) (1 trial)

chlorhexidine (hibitane) (1 trial)

desflurane (suprane) (1 trial)

epinephrine (levophed) (1 trial)

esomeprazole (nexium) (1 trial)

human milk (1 trial)

insulin human (humulin) (1 trial)

lactobacillus reuteri (1 trial)

mifepristone (mifeprex) (1 trial)

misoprostol (cytotec) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arteriovenous Fistula (Phase 4)

Brain Neoplasms (Phase 4)

Cardiovascular Diseases (Phase 4)

Carpal Tunnel Syndrome (Phase 3)

Chronic Pain (Phase 4)

Congenital Abnormalities (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Fistula (Phase 4)

Fractures, Bone (Phase 3)

Hip Fractures (Phase 3)

Hydrocephalus (Phase 3)

Hypertension (Phase 3)

Hypertension, Pulmonary (Phase 3)

Ischemia (Phase 4)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Metabolic Diseases (Phase 4)

Osteoarthritis (Phase 4)

Pain, Postoperative (Phase 4)

Poisoning (Phase 2)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Reperfusion Injury (Phase 4)

Syndrome (Phase 3)

Urinary Bladder, Overactive (Phase 4)

Vesico-Ureteral Reflux (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 42
  • # of Trial APIs: 55